Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group
- Creators
- Sroussi, Marine
- Elaidi, Reza
- Fléchon, Aude
- Lorcet, Marianne
- Borchiellini, Delphine
- Tardy, Magalie
- Gravis, Gwenaelle
- Guérin, Mathilde
- Laguerre, Brigitte
- Estrade, Florian
- Delva, Rémi
- Barthélémy, Phillipe
- Loriot, Yohann
- Lavaud, Pernelle
- Lebret, Thierry
- Neuzillet, Yann
- Penel, Nicolas
- Houédé, Nadine
- Pouessel, Damien
- Rousseau, Benoit
- Mussat, Elodie
- Gross-Goupil, Marine
- Culine, Stéphane
- Gauthier, Hélène
- Gobert, Aurélien
- Rouprêt, Morgan
- Huillard, Olivier
- Tartas, Sophie
- Radulescu, Camélia
- Allory, Yves
- Oudard, Stéphane
- Others:
- Hôpital Européen Georges Pompidou [APHP] (HEGP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
- Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL] ; Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS) ; Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
- Centre de Recherche en Cancérologie de Marseille (CRCM) ; Aix Marseille Université (AMU)-Institut Paoli-Calmettes ; Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Institut Paoli-Calmettes ; Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)
- Centre Eugène Marquis (CRLCC)
- Centre Paul Papin ; CRLCC Paul Papin
- Les Hôpitaux Universitaires de Strasbourg (HUS)
- Oncologie génito-urinaire ; Département de médecine oncologique [Gustave Roussy] ; Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR)
- Département de médecine oncologique [Gustave Roussy] ; Institut Gustave Roussy (IGR)
- Hôpital Foch [Suresnes]
- Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille) ; Université de Lille-UNICANCER
- Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
- Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM) ; CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
- Institut Claudius Regaud
- Hôpital Henri Mondor ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Département d'oncologie médicale ; Institut Bergonié [Bordeaux] ; UNICANCER-UNICANCER
- Hopital Saint-Louis [AP-HP] (AP-HP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- CHU Pitié-Salpêtrière [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Service d'Urologie [CHU Pitié-Salpêtrière] ; CHU Pitié-Salpêtrière [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Hospices Civils de Lyon (HCL)
Description
BACKGROUND:Neuroendocrine carcinoma of the urinary bladder (NCUB) is rare, accounting for < 1% of bladder cancer cases, with scarce reported data available.MATERIALS AND METHODS:We retrospectively reviewed the data from patients with NCUB treated at French institutions. The objectives were to describe the patient characteristics, treatments received, and outcomes (ie, disease-free survival [DFS], progression-free survival, overall survival [OS]) and investigate the prognostic factors.RESULTS:From 1997 to 2017, we included 236 patients, 173 with early-stage NCUB and 63 with advanced-stage NCUB. For those with early-stage disease, the median DFS was better for the patients who had received cisplatin-based chemotherapy compared with carboplatin (hazard ratio [HR], 1.95; 95% confidence interval [CI], 1.1-3.46), with no difference found between the neoadjuvant and adjuvant settings (HR, 1.1; 95% CI, 0.61-1.97). The median OS was 36 months (95% CI, 29-43 months) for stage I and II, 26 months (95% CI, 18 months to not reached) for stage IIIA, 16 months (95% CI, 12-21 months) for stage IIIB. The HR for stage IIIB compared with stage I/II was 2.6 (95% CI, 1.5-4.4). The DFS at 6 months was associated with OS (HR, 7.8; 95% CI, 4.1-15.0). For patients with metastases at diagnosis who had received chemotherapy, the median progression-free survival was 9 months (95% CI, 8-11) for first-line cisplatin and 6 months (95% CI, 4-13 months) for carboplatin; the median OS was 13 months (95% CI, 9-15 months). A high-risk Bajorin score (HR, 11.5; 95% CI, 1.2-112.6) and the use of carboplatin (HR, 2.26; 95% CI, 1.03-4.96) were associated with worse outcomes.CONCLUSIONS:In early-stage disease, a shorter DFS was associated with worse OS, and the use of cisplatin was associated with better OS. For the patients with metastases at diagnosis, a high-risk Bajorin score and the use of carboplatin were associated with worse outcomes.
Abstract
International audience
Additional details
- URL
- https://hal.umontpellier.fr/hal-02556645
- URN
- urn:oai:HAL:hal-02556645v1
- Origin repository
- UNICA